Sleep

Data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

The efficacy of GLP-1 inhibitors in weight loss has introduced them as a means of also addressing obstructive sleep apnea in sleep medicine.

Check out this year's top 5 pieces of sleep coverage that cover topics surveying the benefits of supplements, novel developments in obstructive sleep apnea, and the negative effects of phone addiction.

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

New insights underscore the value of considering sleep variability when addressing inequities in pediatric sleep health.

Resistance training plus aerobic exercise had the greatest impact on patients' obstructive sleep apnea (OSA).

This analysis provides much-needed robust data on the efficacy of heat-cold therapy for mitigating discomfort and insomnia in restless legs syndrome (RSL).

A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.

Based on their findings, the researchers suggest a potential need for screening for coexisting sleep disorder symptoms in patients with respiratory symptoms.

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist.

Both music combined with sleep hygiene and sleep hygiene alone significantly improved pregnancy related insomnia, a new study finds.

Research further shows a significant association between patients with psoriasis and an increased incidence of obstructive sleep apnea (OSA).

A systematic review analyzing sleep quality and the impact of zinc supplements reveals glaring gaps in knowledge in this area despite suggested benefits, demonstrating the need for future research.

A recent data analysis draws correlations between nurses’ experience of insomnia and presenteeism, and the impact these factors have on patient care.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

Though magnesium has long been seen as a potential sleep aid, the authors say the new form of magnesium salt may provide a clearer benefit.

A systematic review on diagnostic challenges and burden related to idiopathic hypersomnia gave insights into the extensive difficulties associated with the condition.

Mark Bleackley, PhD, Incannex, discusses the notable and surprising observations from the ongoing RePOSA study, and the developmental challenges they have encountered with their cannabinoid pharmacotherapy for patients with obstructive sleep apnea.

A new study found physical activity held more weight in the link between the joint exposure of sleep duration, metabolic equivalent of task, and Healthy Eating Index (HEI)-2015 and metabolic-associated fatty liver disease (MAFLD).

Caitlin Kindberg, a patient advocate from Nashville, Tennessee, discusses her experience finding proper treatment for idiopathic hypersomnia and the challenges associated with living with this condition.

Christopher Depner, PhD, assistant professor of health and kinesiology, University of Utah, speaks to the current reliability of wearable sleep devices to impact health outcomes, privacy concerns, and more.

Mark Bleackley, PhD, chief scientific officer of Incannex, discusses in further detail the need for a pharmacotherapy like IHL-42X in obstructive sleep apnea (OSA) and the medication's underlying mechanisms.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps.

Mark Bleackley, PhD, chief scientific officer, Incannex, details the progress of the ongoing RePOSA trial, which is assessing the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA).